Dynavax Technologies Azioni (NASDAQ: DVAX)

Ultime notizie per Dynavax Technologies (NASDAQ:DVAX) Azioni

DYNAVAX TECHNOLOGIES CORP

Dynavax Technologies

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

Analysts' ratings for Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $23.4, a high estimate of $33.00, and a low estimate of $10.00. A 2.5% drop is evident in the current average compared to the previous average price target of $24.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746651652_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Dynavax Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dynavax Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dynavax Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Dynavax Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dynavax Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Dynavax Technologies</h2>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Key Indicators: Dynavax Technologies's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Dynavax Technologies showcased positive performance, achieving a revenue growth rate of 29.56% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dynavax Technologies's net margin is impressive, surpassing industry averages. With a net margin of 9.79%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 1.1%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dynavax Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Dynavax Technologies's debt-to-equity ratio is below the industry average at 0.43, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

DVAX

Breaking Down Dynavax Technologies: 5 Analysts Share Their Views

JMP Securities analyst Roy Buchanan maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Market Outperform and lowers the price target from $33 to $31.

News

Price Target

JMP Securities Maintains Market Outperform on Dynavax Technologies, Lowers Price Target to $31

WIIM

Dynavax Technologies shares are trading lower after the company reported worse-than-expected Q1 financial results.

FDA Commissioner Marty Makary on Tuesday named Vinay Prasad the next director of the U.S. Food and Drug Administration&#8217;s (FDA) Center of Biologics Evaluation and Research (CBER).
Dr. Prasad has openly criticized the biopharma industry and the FDA for using accelerated approvals broadly based on surrogate endpoints.
&#8220;We are surprised by the announcement because it seems to be in stark contrast to themes and initiatives that have been laid out by Dr. Makary, and it comes on the heels of large personnel departures across the FDA, raising questions on the ability to meet review timelines,&#8221; writes <a href="https://www.benzinga.com/topic/william-blair">William Blair </a>of Blue Matrix.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufac" rel="noreferrer noopener">FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight</a>
Analyst Matt Phipps adds that there are many questions about how Prasad will shape regulatory decisions as the new head of CBER. Investors also seem confused about what CBER regulates compared to the Center of Drug Evaluation and Research (CDER).
Generally, drugs like antibodies, bispecifics and antibody-drug conjugates (ADCs) are reviewed by CDER, even though they use biologics license applications (BLAs).
CBER, on the other hand, oversees gene and cell therapies, vaccines and some other biological products. CDER typically handles therapeutic antibodies, proteins, cytokines and enzymes.
Blair wrote on Tuesday that for cell and gene therapies stocks that have reacted negatively, there are outstanding questions and increased uncertainty now as the analyst waits to see whether Makary or Prasad will have more impact on the guidelines and regulatory development requirements for these novel therapies, particularly in rare diseases.
Since being confirmed as commissioner, Makary has advocated for more accelerated approval opportunities for ultrarare diseases or therapies with overwhelming efficacy.
The vaccine space continues to face negative sentiment from HHS Secretary Robert F. Kennedy Jr., who requested placebo-controlled studies for new vaccine approvals.
Prasad&#8217;s appointment at CBER will likely continue to pressure this sector.
&#8220;Under Secretary Kennedy&#8217;s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to licensure — a radical departure from past practices,&#8221; HHS <a target="_blank" href="https://edition.cnn.com/2025/04/30/health/hhs-vaccine-placebo-testing" rel="noreferrer noopener">told</a> CNN in a statement Wednesday.
Blair writes that from the coverage list, Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has seen a sharp sell-off and remains in a difficult position with a politically out-of-favor mRNA vaccine technology and a potentially more restrictive CBER head and review process for new vaccine products.
In contrast, Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) remains largely insulated given that Heplisav is approved and the analyst sees less scrutiny on adult vaccines that are not being pushed as mandatory.
Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) fell 18%, Solid Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) closed 20.3% lower, Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock closed 29% lower, Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) stock closed 12% lower, Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock closed 27% lower, Moderna fell 12%, Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) fell 4.2%, and Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) closed 3.2% on Tuesday. Virtus LifeSci Biotech Clinical Trials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBC#NYSE">BBC</a>) closed 9.74% lower at $17.15 and SPDR Series Trust SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) fell 6.63% to $77.17 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45237060/despite-nikes-executive-overhaul-ongoing-challenges-persist-says-analyst" target="_blank" rel="noreferrer noopener">Nike Revamps C-Suite, &#8216;Win Now&#8217; Strategy Faces Profit Pressure: Analyst</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Movers

Trading Ideas

General

CAPR

CRSP

MRNA

NVAX

SLDB

SRPT

TSHA

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $0.04 by 375 percent. This is a 57.14 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $68.16 million which missed the analyst consensus estimate of $70.58 million by 3.43 percent. This is a 34.21 percent increase over sales of $50.79 million the same period last year.

Earnings

Earnings Misses

CORRECTION: Dynavax Technologies Q1 Adj. EPS $(0.11) Misses $0.04 Estimate, Sales $68.16M Miss $70.58M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $21.5, a high estimate of $33.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.15%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744920077_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Dynavax Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Choi &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Sell &#x7C; $10.00&#x7C;$12.00 &#x7C; 
&#x7C;Jason Butler &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Market Outperform&#x7C; $33.00&#x7C;$29.00 &#x7C; 
&#x7C;Edward White &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $31.00&#x7C;$31.00 &#x7C; 
&#x7C;Paul Choi &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Sell &#x7C; $12.00&#x7C;$15.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dynavax Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Dynavax Technologies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Dynavax Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dynavax Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Dynavax Technologies</h2>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Unraveling the Financial Story of Dynavax Technologies</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Dynavax Technologies's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.56%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dynavax Technologies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.79%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dynavax Technologies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.69%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.43.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Dynavax Technologies Stands With Analysts

Goldman Sachs analyst Paul Choi maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Sell and lowers the price target from $12 to $10.

Goldman Sachs Maintains Sell on Dynavax Technologies, Lowers Price Target to $10

BNTX

CVAC

PCVX

Shares of vaccine stocks are trading lower after CDC advisers begins a review of vaccine guidelines and discussed a more narrow use of COVID-19 booster shots.

<ul>
<li>CenterPoint proposal to remove emergency temporary generation costs would lower monthly bills immediately and by as much as $2 per month by 2027</li>
<li>&nbsp;15 generation units would be sent to San Antonio area by Summer 2025 to help meet Texas' current and future energy needs</li>
</ul>

Reported Earlier, CenterPoint Energy Moves To Reduce Electric Bills By Up To $2 Monthly By 2027

Buybacks

Dynavax Intends To Repurchase Approximately $8M

<ul>
<li>Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure</li>
<li>$225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money</li>
</ul>

Financing

Dynavax Has Entered Into Privately Negotiated Exchange And Subscription Agreements To Issue $225M  2.0% Convertible Senior Notes Due 2030

During the last three months, 4 analysts shared their evaluations of Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.75, a high estimate of $33.00, and a low estimate of $12.00. Surpassing the previous average price target of $26.00, the current average has increased by 2.88%.
<img src="https://www.benzinga.com/files/images/story/2025/1740168014_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Dynavax Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dynavax Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Dynavax Technologies's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dynavax Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dynavax Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Dynavax Technologies</h2>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Unraveling the Financial Story of Dynavax Technologies</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Dynavax Technologies's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 15.99%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Dynavax Technologies's net margin excels beyond industry benchmarks, reaching 21.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 2.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dynavax Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.69%, the company showcases efficient use of assets and strong financial health.
Debt Management: Dynavax Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching 0.37. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Dynavax Technologies Stock: Analyst Perspectives (4 Ratings)

Citizens Capital Markets analyst Jason Butler maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Market Outperform and raises the price target from $29 to $33.

Citizens Capital Markets Maintains Market Outperform on Dynavax Technologies, Raises Price Target to $33

HC Wainwright &amp; Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and maintains $31 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $31 Price Target

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent. The company reported quarterly sales of $72.03 million which missed the analyst consensus estimate of $72.70 million by 0.92 percent. This is a 29.56 percent increase over sales of $55.60 million the same period last year.

Earnings Beats

Dynavax Technologies Q4 GAAP EPS $0.05 Beats $0.04 Estimate, Sales $72.03M Miss $72.70M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CENX

CERS

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Dynavax Confirms That Deep Track Capital Submitted Letter To Nominate Four Candidates To Stand For Election To Board; Says Meaningful Board Change Already Underway

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reflecting updated views and recent competitive <a target="_blank" href="https://www.benzinga.com/quote/DVAX" rel="noreferrer noopener">dynamics for vaccines</a>.
Goldman Sachs analyst Paul Choi has downgraded Dynavax to Sell from Neutral and cut the <a target="_blank" href="https://www.benzinga.com/quote/DVAX/analyst-ratings" rel="noreferrer noopener">price target from $15 to $12</a>. He notes growing competition in the shingles vaccine market, which could reduce the potential value of the Z-1018 program and add uncertainty to its long-term revenue.
Potential convenience improvements come from GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Shingrix with the company's pre-filled syringes, which have been accepted for review by <a target="_blank" href="https://www.benzinga.com/25/02/43492835/gsk-launches-share-buyback-of-around-25-billion-after-better-than-expected-q4-earnings-raises-long-term-annual-sales-forecast-to-over-50-billion" rel="noreferrer noopener">both the FDA and EMA</a> (U.S. decision expected by 20 June).
Dynavax is conducting a Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to GSK's Shingrix in 441 healthy adults aged 50 to 69.
Choi also points to uncertain demand for repeat hepatitis B vaccinations in the 2030s, which may impact Heplisav-B's outlook beyond its peak sales. Despite its market share gains, questions remain about the FDA and ACIP's regulatory stance on vaccines in the U.S.
Last month,&nbsp;Dynavax announced preliminary HEPLISAV-B net product revenue of&nbsp;$268 million&nbsp;for 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42945098/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-highlights" rel="noreferrer noopener">up 26% year-over-year</a>.
HEPLISAV-B net product revenue reached&nbsp;$71 million&nbsp;for the fourth quarter of 2024, up 39%.
In May 2024, the FDA issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38818397/fda-declines-to-approve-expanded-use-of-dynavaxs-hepatitis-b-vaccine-in-hemodialysis-patients" rel="noreferrer noopener">regimen of HEPLISAV-B</a>.&nbsp;
Dynavax is expected to report fourth-quarter earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43548293/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-" rel="noreferrer noopener">on 20 February</a>.
As per data from Benzinga Pro, analysts estimate Q4 adjusted EPS of $0.04, with sales of $72.92 million.
Analysts forecast 2024 sales of $278.13 million and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">adjusted EPS of $0.12</a>.
Price Action: DVAX stock is down 4.13% at $12.66 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43629227/nano-cap-lipella-pharmaceuticals-stock-jumps-on-positive-trial-data-in-patients-with-sore-mouth-membranes" target="_blank" rel="noreferrer noopener">Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes</a></li>
</ul>

Downgrades

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty

Dynavax shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell.

Press Releases

Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer

Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

Deep Track Capital Releases Investor Presentation on Dynavax Technologies

Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

Comments

Dynavax Technologies

Notizie

Ultime notizie per Dynavax Technologies (NASDAQ:DVAX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO